Zura Bio Limited (ZURA)
ZURANASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$1.41
-0.0205 (-1.43%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $1.41 -1.39%
- Market cap
- $135.83m
- P/E
- –
- EPS, last 4 quarters
- $-1.12
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9342 to $7.44
- Average volume
- –
- Previous close
- $1.43
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $10.67, +657.5% from here
Earnings
next estimate $-0.2000Next report
Dec 2025
-172.2%
Mar 2026
-29.4%
Jun 2026
-5.0%
Sep 2026
+9.1%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$18.41m | -$25.50m | -$29.32m | -$28.77m |
| Net income | -$17.18m | -$24.22m | -$26.30m | -$25.82m |
News
8 latest- Biotech Stocks In Focus: PEPG Jumps 114%, ZURA Rises 15%, NTHI Gains 13% RTTNews · 1 day ago
- Zura Bio Discontinues Tibulizumab Development In Hidradenitis Suppurativa After Phase 2 Setback RTTNews · 3 days ago
- Biotech Stocks Move Higher: ZURA Surges 21%, PLUR Gains 13%, WVE Rises 7%, KNSA Advances RTTNews · Oct 27, 2026
- Zura Reports Wider Loss In Q2; Expects Phase 2 TibuSHIELD Data In Q2 2026 RTTNews · Aug 12, 2026
- Tenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement RTTNews · Jun 30, 2026
- Tenaya Therapeutics Appoints Eric Hyllengren As Chief Financial Officer RTTNews · Jun 29, 2026
- Wedbush Initiates Coverage of Zura Bio (ZURA) with Outperform RecommendationFintel · Feb 9, 2026
- Zura Bio (ZURA) Price Target Increased by 20.00% to 16.32Fintel · Dec 6, 2025
The company
Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura's pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- Caribbean
- Website
- zurabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.